We are oncologists. We are scientists.<br />
We are entrepreneurs. We are Dayton Therapeutics

We are oncologists. We are scientists.
We are entrepreneurs. We are Dayton Therapeutics

Dr Felix Dahm

Dr Felix Dahm

Chief Executive Officer

Dr Dahm completed his M.D. at the Medical School of the Johannes Gutenberg University in Mainz, Germany, in 2002…

Read more
Dr Gabriel Markson

Dr Gabriel Markson

Chief Financial Officer

Dr Markson completed his PhD in molecular biology at the MRC Human Genome Mapping Project and…

Read more
Prof Dr Christoph Renner

Prof Dr Christoph Renner

Chief Medical Officer

Prof Dr Renner completed his M.D. at the Medical School of the University of Cologne, Germany in 1993…

Read more
Dr Thilo Zander

Dr Thilo Zander

Chief Scientific Officer

Dr Zander received his medical degree from the Medical School of Albert-Ludwigs University of Freiburg, Germany in 2001…

Read more
Dr Pawel Gasiorowski

Dr Pawel Gasiorowski

Head of Data Science

Dr Pawel Gasiorowski is an expert in the area of technological innovation and software engineering.
He possesses an extensive…

Read more
Dr Martin Goodson

Dr Martin Goodson

CEO Evolution AI

Martin is Chief Scientist and CEO of Evolution AI. He is also the Chair of the Royal Statistical Society Data Science…

Read more
Minami Haruko

Minami Haruko

Japan Representative
Dayton Therapeutics

Priya Jambhekar

Priya Jambhekar

Regulatory Consultant
EAS Consulting

Dr Nienke Lubben

Dr Nienke Lubben

Partner and Patent Attorney
HGF

Miranda Squire

Miranda Squire

Creative Director and Designer
Studio Moxi

Dr Felix Dahm Close

Dr Felix Dahm

Chief Executive Officer

Dr Dahm completed his M.D. at the Medical School of the Johannes Gutenberg University in Mainz, Germany, in 2002. He was a resident in visceral and transplantation surgery at the University Hospital in Zurich, Switzerland, where he also completed a postdoc in the hepatobiliary and transplant lab. In 2007 he joined The Boston Consulting Group and worked on multiple projects across the healthcare industry and value chain, with a focus on pharmaceuticals & biotechnology. In 2011 he became part of the commercial operations leadership team at Nycomed in Zurich, where he was responsible for the commercial interface to R&D and was intimately involved in the sale to Takeda for EUR 9.6 Bn. From 2012, Felix was a member of the Executive Committee at Gambro in Lund, Sweden, responsible for the R&D pipeline and Interim President of the BU Chronic and co-responsible for the sale to Baxter International for USD 4 Bn. In 2014 he joined the Executive Committee of BSN medical in Hamburg, Germany, responsible for R&D, Scientific & Medical Affairs, Regulatory Affairs and as Interim Head of Global Commercial. He was co-responsible for the sale to SCA for EUR 2.74 Bn in 2017.

Dr Dahm co-founded E3 Life AG, a lifescience investment boutique, in Zug, Switzerland in 2017. Since its inception, E3 Life has worked on multiple M&A processes in biotech and medtech, and is currently engaged in several lifescience investments together with large institutional investors. E3 Life has a special interest in clinical oncology, and how digital and Al technologies can accelerate cancer therapeutic development and application. Dr Dahm is a co-founder of Dayton Therapeutics AG.

Dr Gabriel Markson Close

Dr Gabriel Markson

Chief Financial Officer

Dr Markson completed his PhD in molecular biology at the MRC Human Genome Mapping Project and Cambridge Institute for Medical Research, University of Cambridge, UK.

Subsequently he joined Cambridge Consultants and worked on multiple deals where he was involved in the commercial and technical due diligence of biopharma/biotech companies. In 2010 he became part of the commercial operations team at Nycomed in Zurich, where he responsible for technical evaluation and valuation of in-licensing deals, contributed to a major biotech acquisition in China, and was heavily involved in the sell-side due diligence resulting in the sale to Takeda for EUR 9.6 Bn. After the sale of Nycomed to Takeda, he joined Gambro where he was responsible for corporate strategy development and implementation, and heavily involved in the sell-side due diligence and sale to Baxter for USD 4 Bn, as well as Master Planner for the subsequent integration. In 2014, Dr Markson joined BSN medical as Head of Strategic Planning and Business Development, where he was responsible for corporate strategy development and implementation, business development, business intelligence, and heavily involved in the sell-side due diligence and sale to SCA for EUR 2.74 Bn in 2017.

Dr Markson co-founded E3 Life AG, a lifescience investment boutique, in Zug, Switzerland in 2017. Since its inception, E3 Life has worked on multiple M&A processes in biotech and medtech, and is currently engaged in several lifescience investments together with large institutional investors. E3 Life has a special interest in clinical oncology, and how digital and Al technologies can accelerate cancer therapeutic development and application. Dr Markson is a co-founder of Dayton Therapeutics AG.

Prof Dr Christoph Renner Close

Prof Dr Christoph Renner

Chief Medical Officer

Prof Dr Renner completed his M.D. at the Medical School of the University of Cologne, Germany in 1993. He then trained in Internal Medicine at the University Hospital Saarland where he received his board certification in Oncology/Haematology in 2001. His special area of expertise is primarily within Haematology and Lymphoma, including high-dose chemotherapy and autologous stem cell transplantation. In 2004, he was appointed Professor of Immune and Gene Therapy at the University Saarland and moved to the University Zurich, Switzerland, in 2005, where he held different appointments until December 2012. His latest appointment was head of the Department of Internal Medicine and Oncology, head of the cancer centre and Professor for clinical and experimental oncology at the University of Zurich. Prof Dr Renner joined the Swiss Tumor Institute (STI) in January 2013 and started the Cancer Centre initiative at Clinic Hirslanden, the largest private hospital group in Switzerland. He is currently the chair of the Cancer Centre, the head of the Haematology and Lymphoma Unit and programme director for cellular therapies including stem cell transplantation and CART-cells. He is Professor for Medical Oncology at the University of Basel.

Prof Dr Renner has published over 110 articles and reviews in scientific journals. He has also contributed chapters to a dozen cancer-related textbooks. His lab interests are mainly on antibody development and new immunological approaches for cancer treatment. He has a strong background in translational research and served as Pl for national and international phase I to phase Ill trials in Haematology/Oncology. He is a member of different research organisations and served on the board of the Swiss Group for Clinical Cancer Research until the end of 2013. In addition, he serves on the scientific advisory board of various biotech start-ups and is a co-founder of lmmunOs Therapeutics AG and Dayton Therapeutics AG.

Dr Thilo Zander Close

Dr Thilo Zander

Chief Scientific Officer

Dr Zander received his medical degree from the Medical School of Albert-Ludwigs University of Freiburg, Germany in 2001. He was trained at Klinikum Offenburg, Germany, the Cantonal Hospital Lucerne, Switzerland, and Barts Cancer Centre Lymphoma in London, UK. He received his board certification in Internal Medicine and Medical Oncology in 2008. Dr Zander has more than fifteen years of experience in haemato-oncology, immunology and drug repurposing. He is the founder and head of the Lymphoma Service at the Comprehensive Cancer Centre in Lucerne which is one of the largest of the country. As member of the steering committee of the local stem cell transplant network he successfully co-developed the program in collaboration with the University of Berne.

Dr Zander is a voting member of the Swiss Group for Clinical Cancer Research (SAKK) Lymphoma Project Group. Within this network he worked on the development of Nelfinavir as an orphan drug in relapsing and refractory Multiple Myeloma, FDA and Swissmedic Orphan drug status was granted 2017. He has extensive experience in clinical trials in haemato-oncology and has been the Pl or a co-investigator for numerous multi-centre trials.

Currently he serves as principal investigator of a multi-centre Phase 2 trial investigating the optimal use of pomalidomide in relapsing and refractory multiple myeloma. Dr Zander is a co-founder of Dayton Therapeutics AG.

Dr Pawel Gasiorowski Close

Dr Pawel Gasiorowski

Head of Data Science

Dr Pawel Gasiorowski is an expert in the area of technological innovation and software engineering. He possesses an extensive knowledge and experience in the area of software architecture design, development and commercial implementation. Pawel is a Senior Research Fellow and Associate Lecturer at London Metropolitan University. Pawel is a computer software engineer by training with strong emphasis on Data Science and Machine Learning and holds a PhD on simulation based analysis and modelling from London Metropolitan University, UK.

Dr Martin Goodson Close

Dr Martin Goodson

CEO Evolution AI

Martin is Chief Scientist and CEO of Evolution AI. He is also the Chair of the Royal Statistical Society Data Science Section and runs the largest machine learning community in Europe, London Machine Learning Meetup.

Originally a bioinformatician, Martin has a background as a Statistical Geneticist at the University of Oxford, and Genomics Specialist at the MRC Human Genome Mapping Project, University of Cambridge.